- Home
- SVRE vs ENVB Comparison
SVRE vs ENVB Comparison
Compare SVRE & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRE
- ENVB
- Stock Information
- Founded
- SVRE 2014
- ENVB 1994
- Country
- SVRE Israel
- ENVB United States
- Employees
- SVRE N/A
- ENVB N/A
- Industry
- SVRE
- ENVB Biotechnology: Pharmaceutical Preparations
- Sector
- SVRE
- ENVB Health Care
- Exchange
- SVRE Nasdaq
- ENVB Nasdaq
- Market Cap
- SVRE 2.6M
- ENVB 4.4M
- IPO Year
- SVRE 2022
- ENVB N/A
- Fundamental
- Price
- SVRE $0.12
- ENVB $0.44
- Analyst Decision
- SVRE
- ENVB Strong Buy
- Analyst Count
- SVRE 0
- ENVB 1
- Target Price
- SVRE N/A
- ENVB $10.00
- AVG Volume (30 Days)
- SVRE 4.9M
- ENVB 1.2M
- Earning Date
- SVRE 08-27-2024
- ENVB 11-11-2024
- Dividend Yield
- SVRE N/A
- ENVB N/A
- EPS Growth
- SVRE N/A
- ENVB N/A
- EPS
- SVRE N/A
- ENVB N/A
- Revenue
- SVRE $458,952.00
- ENVB N/A
- Revenue This Year
- SVRE N/A
- ENVB N/A
- Revenue Next Year
- SVRE $422.52
- ENVB N/A
- P/E Ratio
- SVRE N/A
- ENVB N/A
- Revenue Growth
- SVRE N/A
- ENVB N/A
- 52 Week Low
- SVRE $0.12
- ENVB $0.36
- 52 Week High
- SVRE $1.50
- ENVB $2.92
- Technical
- Relative Strength Index (RSI)
- SVRE 30.03
- ENVB 46.38
- Support Level
- SVRE $0.13
- ENVB $0.36
- Resistance Level
- SVRE $0.14
- ENVB $0.49
- Average True Range (ATR)
- SVRE 0.01
- ENVB 0.04
- MACD
- SVRE 0.00
- ENVB 0.00
- Stochastic Oscillator
- SVRE 20.63
- ENVB 57.61
About SVRE SaverOne 2014 Ltd.
Saverone 2014 Ltd provides driver protection solutions. The company develops and deploys ADAS technologies for transportation safety and driver assistance. The company's product restricts the driver from surfing, communicating, and receiving alerts while driving. The Company has developed a system that provides a solution to the problem of distracted driving caused by cell phone use, which endangers the driver, passengers, other drivers on the road, and pedestrians.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.